Showing results (341-350 of 389) with videos related to
Sort By:
Pageof 39
JTO Clinical and Research Reports|June 19, 2025
Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003)Hidenobu Ishii, Koichi Azuma, Yuta Yamanaka, et al.International Journal of Clinical Oncology|January 19, 2011
High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatinYasuhiro Kidera, Taroh Satoh, Shinya Ueda, et al.Cancer|February 6, 2020
Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS studyTakayuki Takahama, Koichi Azuma, Mototsugu Shimokawa, et al.Nature Communications|February 27, 2023
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trialJuliann Chmielecki, Tony Mok, Yi-Long Wu, et al.European Journal of Cancer (Oxford, England : 1990)|May 27, 2026
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARDZofia Piotrowska, Sarah B Goldberg, Jonathan W Goldman, et al.International Journal of Clinical Oncology|March 5, 2019
Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LCShunichi Sugawara, Kazuhiko Nakagawa, Nobuyuki Yamamoto, et al.Molecular Systems Biology|November 6, 2013
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanismsJiannong Li, Keiryn Bennett, Alexey Stukalov, et al.The Lancet. Healthy Longevity|September 13, 2022
Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trialYoshihito Kogure, Shunichiro Iwasawa, Hideo Saka, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 22, 2018
Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian SubsetByoung Chul Cho, Busayamas Chewaskulyong, Ki Hyeong Lee, et al.Cancer Science|July 2, 2017
Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancerKohei Otsubo, Kaname Nosaki, Chiyo K Imamura, et al.Pageof 39